Electric bus manufacturer faces litigation, moves operations west

GreenPower Motor Company (NASDAQ: GP) said it completed the fourth tranche of a preferred share financing, issuing 1,500 Series A Convertible Preferred Shares in a private placement for gross proceeds of US$1.425 million. Shares convert into common stock at a rate tied to stated value plus 125% of the prior day’s NASDAQ closing price. A 5% placement fee applies.

GreenPower Motor Company (NASDAQ: GP) said it completed the third tranche of a preferred-share financing on June 30, 2026, issuing 1,500 Series A Convertible Preferred Shares for gross proceeds of $1.425M. The company and investor amended the agreement to increase the stated value issuable by $2M. Conversion terms reference stated value plus amounts and 125% of prior-day NASDAQ close.

GreenPower Motor Co. (NASDAQ:GP) reported a 40.5% drop in short interest in May, to 145,787 shares as of May 15 from 244,992 on April 30. Short interest was about 4.0% of shares, with a short-interest ratio of 0.7 days. On Thursday, GP traded at $1.13. Analysts cited include Weiss Ratings (sell e+) and BTIG (neutral).

Royal Caribbean Cruises (RCL) has been upgraded by Bank of America and Deutsche Bank, citing a recent pullback and a Sandals Resorts partnership. The stock is down 13% in the past month and 24% in the past quarter, but has a 3-year total shareholder return of over 100%. Analysts estimate a fair value of $346.92, suggesting undervaluation. Revenue growth is expected from enhanced guest experiences and loyalty programs, but risks include consumer travel budgets and fuel costs.

BNP Paribas upgraded AT&T (T) to Outperform, raising its price target to $30. The firm cited a more rational U.S. wireless market and expected ARPU growth, which could boost revenue, EBITDA, and free cash flow. AT&T reported Q2 2026 revenues of $31.6B, EBITDA of $12.3B, and free cash flow of $4.7B, with plans to return $45B to shareholders by 2028. Concerns include high debt and legacy service declines.

Gilead Sciences (GILD) expanded its royalty-free licensing for lenacapavir to include a once-yearly HIV PrEP formulation, covering 120 lower-income countries. The move aims to accelerate manufacturing and secure market dominance. Gilead's HIV sales grew 12% YoY to $5.7B in Q2 2026, but the company reported losses due to acquisition-related R&D charges.